Kumar Neil 4

What Happened

• Neil Kumar, CEO of BridgeBio Pharma (BBIO), sold a total of 26,103 shares in open-market transactions on May 21, 2026, generating aggregate proceeds of approximately $1,812,522.
• Individual transactions reported:
  • 2,256 shares at $67.57 — $152,435
  • 6,725 shares at $68.30 — $459,334
  • 5,072 shares at $69.22 — $351,102
  • 11,250 shares at $70.48 — $792,916
  • 800 shares at $70.92 — $56,735
• These were sales (code S) — routine disposition of shares rather than purchases (not a bullish signal).

Key Details

• Transaction date: May 21, 2026. Form 4 filed: May 26, 2026 (appears filed after the typical 2-business-day window for Form 4s).
• Prices: sales executed across price ranges from ~$66.81 to $70.97 per share (weighted-average ranges are footnoted in the filing).
• Total shares sold: 26,103; total proceeds: ≈ $1.81 million.
• Notable footnotes:
  • F1: Sales were effected pursuant to a Rule 10b5-1 sales plan adopted March 31, 2025 (pre-scheduled trading plan).
  • F2–F6: Filing reports weighted-average sale-price ranges and offers to provide per-price breakdowns on request.
  • F7: Reporting person disclaims beneficial ownership except to extent of pecuniary interest.
• Shares owned after the transaction: not specified in the information provided.

Context

• Sales under a 10b5-1 plan are typically pre-arranged and can be routine (the plan reduces the implication that the insider traded on inside information).
• Because these are outright sales (code S), they indicate liquidation of holdings rather than a vote of confidence via purchase.